GcMaf replacement is licensed in Germany, says CEO
PATIENTS in Guernsey have not received GcMaf for 20 months, while the product they have been receiving, Goleic, is licensed as a vitamin supplement in Germany and should be allowed into the island, Immuno Biotech CEO David Noakes said last night.
More than 100 people attended an emotive meeting at St Pierre Park Hotel to discuss the future of GcMaf, after its importation was banned over concerns from the Medicines and Healthcare Products Regulatory Agency about how it was produced.
It is claimed GcMaf cures many conditions, including cancer and autism, and has been widely marketed by Guernsey-registered Immuno Biotech.
But last night's talk ended up looking at another of the company's products, Goleic.
Mr Noakes, pictured, said while people have ordered GcMaf, over the last 20 months, Goleic has been issued instead.
After the meeting he said that GcMaf was on the 'Vitamin D' pathway and that German authorities did not test supplements in the same way as the MHRA tested medicines.
He also highlighted that as it was licensed in the EU, it should be allowed into Guernsey, but it was still being stopped at the border.
